Latest Immunotherapy Approaches in Multiple Myeloma

Video

This video highlights novel approaches using immunotherapies and vaccines for advancing treatment in multiple myeloma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Ivan Borrello, MD, of Johns Hopkins University in Baltimore, Maryland, discusses novel approaches with immunotherapies and vaccines for advancing treatment in multiple myeloma.

      Borrello gave a presentation on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

      Recent Videos
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Secondary Malignancies Risk Still in Question Following CAR T-cell Therapy for Lymphoma
      A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
      Study Aims to Address CAR T Accessibility Among Disadvantaged Groups
      Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
      Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia
      Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
      Menin Inhibitor Developments Move Acute Myeloid Leukemia Landscape Forward
      Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
      Advocate Outlines Resources for Chronic Myeloid Leukemia Population
      Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
      Expert Highlights Risk Factors for Disease Progression in Polycythemia Vera
      Related Content
      An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

      Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports

      Russ Conroy
      April 11th 2025
      Article

      An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

      Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
      October 21st 2024
      Podcast

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

      Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies

      Roman Fabbricatore
      March 17th 2025
      Article

      Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

      Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

      Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

      Rahul Banerjee, MD, FACP;Noopur Raje, MD
      September 2nd 2024
      Podcast

      Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

      BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!

      BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!

      American Society for Transplantation and Cellular Therapy
      March 3rd 2025
      Article

      Overall, BMT CTN 0702 showed no improvement in outcomes with added post-ASCT consolidation as compared to standard lenalidomide maintenance.

      Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

      Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

      Russ Conroy
      February 14th 2025
      Article

      Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.